AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%

Reuters

10/02

AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%

AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572515314"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572515314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572515314?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572515314","market":"us","top_or_hot":-1,"title":"AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the <a href=\"https://laohu8.com/S/01339\">PICC</a>, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the <a href=\"https://laohu8.com/S/01339\">PICC</a>, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL9Nqfjz:1","article_id":"2572515314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572515314","pubTimestamp":1759399242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"血管动力学报告2026财年第一季度业绩；医疗技术销售额增长26.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":0.9},"content_text":"AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    \n\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}